GSK
GSK plc American Depositary Shares (Each representing two Ordinary Shares)
Pharmaceutical Preparations
Best Pharmaceutical Stocks 2026 →
GSK Stock Analysis: Buy, Sell, or Hold?
$50.60
-0.63 (-1.23%)
âŧ
5d:
-1.08%
30d:
+9.36%
90d:
+0.3%
QUANTITATIVE VERDICT
WAIT
LOW Confidence (63%)
Quality Score
41/100
Position
SLIGHTLY HIGH
30-Day Fair Range
$47.45 â $50.90
Position: SLIGHTLY HIGH
Forward P/E & Valuation
10.2x
FAIR
vs 10.3x historical avg
Wall Street Target
$59.12
+16.8% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$48.03 / $51.89
Trend: Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: GSK is fairly priced but lacks strong directional signals. At -0.2% expected growth, valuation appears fair. Wait for clearer setup or better entry on dips.
Get Alerted When GSK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$62.28
Based on 4.1% avg growth
INTRINSIC VALUE TODAY
$38.67
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 10.3x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: GSK is currently trading at $50.60, which is considered slightly high relative to its 30-day fair value range of $47.45 to $50.90. The stock's valuation (Forward PE: 10.2) is in line with its historical norms (10.3). Remarkably, the market is currently pricing in an annual earnings decline of 0.2% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, GSK is in a downtrend. The price is approaching resistance at $51.89. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $59.12 (+16.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, GSK is in a downtrend. The price is approaching resistance at $51.89. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: The stock scores a mixed 44/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $59.12 (+16.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$47.45 -
$50.90
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
62.9%
Trading Range & Key Levels
30-Day Trading Range
$47.45 -
$50.90
Current vs Trading Range
SLIGHTLY HIGH
Support Level
$48.03
Resistance Level
$51.89
Current Trend
Downtrend
Technical data as of
Nov 11, 2026
Quantitative Signal Breakdown
- NEUTRAL: Mixed technical signals (44/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($59.12)
- WARNING: Composite score 41/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Forward P/E (Next Year Est.)
10.21
Wall Street Target
$59.12
(+16.8%)
Revenue Growth (YoY)
4.0%
Earnings Growth (YoY)
-22.8%
Profit Margin
13.0%
Valuation Discount vs History
-0.2% cheaper
PE vs Historical
10.2 vs 10.3
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-0.2%
(market-implied from PE analysis)
1-Year Target
$50.50
(0%)
2-Year Target
$50.40
(0%)
3-Year Target
$50.30
(-1%)
3-Yr Target (if PE normalizes)
(PE: 10â10)
$50.76
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 19.9, Growth: 4.1%)
$111.19
(+120%)
Base:
(SPY PE: 10.2, Growth: 4.1%)
$57.14
(+13%)
Bear:
(PE: 8.7, Growth: 4.1%)
$48.57
(-4%)
đ
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (18x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 17.85 | Current EPS (TTM): $2.87
Bull Case
$97.35
(+92%)
Analyst growth 72.8%, PE expands to 19.6
Base Case
$88.50
(+75%)
Market implied 72.8%, PE stable at 17.9
Bear Case
$34.84
(-31%)
Severe decline -20.0%, PE contracts to 15.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
đĄ
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 10.2 to 10.3
Stabilization Target:
$51.07
(+0.9%)
PE Expansion Potential:
+0.9%
Share GSK Analysis
Share this live GSK analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (GSK)
Bullish
2 Retail Mentions
Reddit / WSB Comments
2
Bullish
Last Tracked
Jul 23, 2026
Daily AI digest
AI Retail Discussion Summary:
Reddit & WallStreetBets discussions on GSK are bullish (sentiment score +0.46) across 2 tracked comments.
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 9:12 AM ET
Data refreshes hourly during market hours. Next update: 10:12 AM
Data refreshes hourly during market hours. Next update: 10:12 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is GSK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ABBV
AbbVie Inc |
STRONG BUY
29 analysts |
$306 | 48 HOLD |
|
BIIB
Biogen Inc |
BUY
36 analysts |
$266 | 43 HOLD |
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1453 | 27 SELL |
|
MRK
Merck & Company Inc |
BUY
28 analysts |
$162 | 50 HOLD |
|
GILD
Gilead Sciences Inc |
STRONG BUY
28 analysts |
$175 | 37 SELL |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive GSK Research Pages
